We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: GPRC5D
MedXY News
EnglishTag

GPRC5D

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Hematology-Oncologyrelapsed/refractoryGPRC5D

Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

By MedXY|Sep 12, 2026

Arlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including pr

Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease
Hematology-OncologyGPRC5D
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
BCMA

Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease

By MedXY|Aug 20, 2026

Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.

When Targeting Becomes a Double-Edged Sword: How Loss of GPRC5D May Fuel Multiple Myeloma Progression
Hematology-OncologyGPRC5Dimmunotherapy resistance

When Targeting Becomes a Double-Edged Sword: How Loss of GPRC5D May Fuel Multiple Myeloma Progression

By MedXY|Apr 12, 2026

Researchers discovered that loss of GPRC5D, a key immunotherapy target in multiple myeloma, not only confers resistance to targeted therapies but actively promotes cancer cell proliferation and competitive fitness—creating a therapeutic par

Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma
Hematology-OncologyBCMAGPRC5D

Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma

By MedXY|Nov 17, 2025

Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 t

Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Hematology-OncologyCAR-TGPRC5D

Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

By MedXY|Nov 17, 2025

In a phase 1 study of 18 heavily pretreated patients, the fully human VHH-based anti-GPRC5D CAR T-cell therapy RD118 achieved a 94.4% overall response rate, 72.2% CR/sCR, median PFS 18.2 months, and an acceptable safety profile with predomi

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities